Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors

被引：72

作者：

Guan, Ronggui ^{[1
]}

Xu, Xiaoyu ^{[1
]}

Chen, Meihui ^{[1
]}

Hu, Haiyan ^{[1
]}

Ge, Hu ^{[1
]}

Wen, Shijun ^{[2
]}

Zhou, Shiyou ^{[3
]}

Pi, Rongbiao ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China

[2] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China

[3] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2013年 / 70卷

基金：

中国国家自然科学基金;

关键词：

RhoA; Rho kinase; Inhibitors; Central nervous system; Fasudil; CENTRAL-NERVOUS-SYSTEM; RHO-ASSOCIATED KINASE; ROCK INHIBITORS; THERAPEUTIC TARGET; FASUDIL; DISCOVERY; POTENT; OPTIMIZATION; DERIVATIVES; 7-AZAINDOLES;

D O I：

10.1016/j.ejmech.2013.10.048

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

RhoA/Rho-kinase pathway plays a pivotal role in numerous fundamental cellular functions including contraction, motility, proliferation, differentiation and apoptosis. The pathway is also involved in the development of many diseases such as vasospasm, pulmonary hypertension, cancer and central nervous systems (CNS) disorders. The inhibitors of Rho kinase have been extensively studied since the Rho/Rho-kinase pathway was verified as a target for a number of diseases. Herein, we reviewed the advances in the studies of the roles of Rho/Rho-kinase in diseases and the development of Rho-kinase inhibitors in recent five years. (C) 2013 Elsevier Masson SAS. All rights reserved.

引用

页码：613 / 622

页数：10

共 71 条

[41] RKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast Cancer [J].

Patel, Ronil A. ;

Forinash, Kara D. ;

Pireddu, Roberta ;

Sun, Ying ;

Sun, Nan ;

Martin, Mathew P. ;

Schoenbrunn, Ernst ;

Lawrence, Nicholas J. ;

Sebti, Said M. .

CANCER RESEARCH, 2012, 72 (19) :5025-5034

[42] RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease [J].

Peng, Fangfang ;

Wu, Dongcheng ;

Gao, Bo ;

Ingram, Alistair J. ;

Zhang, Baifang ;

Chorneyko, Katherine ;

McKenzie, Rick ;

Krepinsky, Joan C. .

DIABETES, 2008, 57 (06) :1683-1692

[43] Preventive and therapeutic effects of the selective Rho-kinase inhibitor fasudil on experimental autoimmune neuritis [J].

Pineda, Arnold Angelo M. ;

Minohara, Motozumi ;

Kawamura, Nobutoshi ;

Matsushita, Takuya ;

Yamasaki, Ryo ;

Sun, Xiaojia ;

Piao, Hua ;

Shimokawa, Hiroaki ;

Kira, Jun-ichi .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 2011, 306 (1-2) :115-120

[44] Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2) [J].

Pireddu, Roberta ;

Forinash, Kara D. ;

Sun, Nan N. ;

Martin, Mathew P. ;

Sung, Shen-Shu ;

Alexander, Brian ;

Zhu, Jin-Yi ;

Guida, Wayne C. ;

Schoenbrunn, Ernst ;

Sebti, Said M. ;

Lawrence, Nicholas J. .

MEDCHEMCOMM, 2012, 3 (06) :699-709

[45] Neuroproteomics approach and neurosystems biology analysis: ROCK inhibitors as promising therapeutic targets in neurodegeneration and neurotrauma [J].

Raad, Mohamad ;

El Tal, Tala ;

Gul, Rukhsana ;

Mondello, Stefania ;

Zhang, Zhiqun ;

Boustany, Rose-Mary ;

Guingab, Joy ;

Wang, Kevin K. ;

Kobeissy, Firas .

ELECTROPHORESIS, 2012, 33 (24) :3659-3668

[46] Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy [J].

Rath, Nicola ;

Olson, Michael F. .

EMBO REPORTS, 2012, 13 (10) :900-908

[47] Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors [J].

Ray, Peter ;

Wright, Jane ;

Adam, Julia ;

Bennett, Johnathan ;

Boucharens, Sylviane ;

Black, Darcey ;

Cook, Andrew ;

Brown, Angus R. ;

Epemolu, Ola ;

Fletcher, Dan ;

Haunso, Anders ;

Huggett, Margaret ;

Jones, Phil ;

Laats, Steven ;

Lyons, Amanda ;

Mestres, Jordi ;

de Man, Jos ;

Morphy, Richard ;

Rankovic, Zoran ;

Sherborne, Brad ;

Sherry, Lorcan ;

van Straten, Nicole ;

Westwood, Paul ;

Zaman, Guido Z. R. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (01) :97-101

[48] Rho-kinase: important new therapeutic target in cardiovascular diseases [J].

Satoh, Kimio ;

Fukumoto, Yoshihiro ;

Shimokawa, Hiroaki .

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2011, 301 (02) :H287-H296

[49] Potent, Selective and Orally Bioavailable Dihydropyrimidine Inhibitors of Rho Kinase (ROCK1) as Potential Therapeutic Agents for Cardiovascular Diseases [J].

Sehon, Clark A. ;

Wang, Gren Z. ;

Viet, Andrew Q. ;

Goodman, Krista B. ;

Dowdell, Sarah E. ;

Elkins, Patricia A. ;

Semus, Simon F. ;

Evans, Christopher ;

Jolivette, Larry J. ;

Kirkpatrick, Robert B. ;

Dul, Edward ;

Khandekar, Sanjay S. ;

Yi, Tracey ;

Wright, Lois L. ;

Srnith, Gary K. ;

Behm, David J. ;

Bentley, Ross ;

Doe, Christopher P. ;

Hu, Erding ;

Lee, Dennis .

JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (21) :6631-6634

[50] Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (Part-II) [J].

Sessions, E. Hampton ;

Chowdhury, Sarwat ;

Yin, Yan ;

Pocas, Jennifer R. ;

Grant, Wayne ;

Schroeter, Thomas ;

Lin, Li ;

Ruiz, Claudia ;

Cameron, Michael D. ;

LoGrasso, Philip ;

Bannister, Thomas D. ;

Feng, Yangbo .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (23) :7113-7118

← 1 2 3 4 5 6 7 8 →